Celgene Corporation (NASDAQ:CELG) most recently reported quarterly actual earnings per share of $1.28 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $1.24. The difference between the estimate and the actual EPS was $0.04 creating a surprise factor of 3.23%. Currently, the company has an impact score of 90. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.141. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $141.785 on the shares. The most bullish brokerage firm has a $162 target, while the most bearish sees the stock headed towards $120. This is according to the 14 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.35. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 14 recommendations taking into account in order to arrive at this number. Of the 14, 14 have a Strong Buy rating and 0 are rating it a Buy.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Celgene Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.